UNI-EN 143:NOTIFICATION
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| | UNI - EN REPORT No | 143 | / | 2013 | | ||||||
| Date of issue: | 2013-11-14 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| NOTIFICATION | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sopharma AD (the “Company") announces that on 13 November 2013 the Company bought 1 000 shares from the capital of Hidroizpmat AD. After this transaction, the share of Sopharma AD in the capital of Hidroizpmat AD increased to 10.02%. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Current report 143 Hidroizomat above 10%.doc Current report 143 Hidroizomat above 10%.doc | Current report 143 Hidroizomat above 10% | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2013-11-14 | Ognian Donev | Executive Director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to None PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
